Mounjaro GLP-1 Weight Loss Tracker

Glapp is a free GLP-1 tracker built by GLP-1 patients and health tech professionals, in collaboration with doctors. It logs your Mounjaro shots, doses and injection sites, tracks weight and side effects, and shows an estimated medication-level curve. It is a tracking and educational tool; it does not replace your care team.

Glapp includes free shot, weight, and side effect tracking, plus estimated medication-level charts. Optional Glapp Max adds full Progress Reports, Milestones, and Predictions. Built by GLP-1 patients and health tech professionals in collaboration with doctors.

Each logged shot records the site you used, and Glapp suggests the next site in your rotation (abdomen, thigh or upper arm) so recent sites are easy to see. Follow the rotation your care team recommends.

Tirzepatide reaches peak blood levels 8 to 72 hours after an injection, and many people notice appetite changes within the first week or two. Weight change usually becomes visible over one to three months as the dose steps up. In the SURMOUNT-1 trial, average weight loss at 72 weeks was about 15% to 21% depending on dose, versus about 3% with placebo. Individual results vary. Tracking does not change how the medication works; it helps you and your clinician see your own pattern.

Tirzepatide does not directly damage hair follicles, but some people experience temporary hair shedding during rapid weight loss. This is usually telogen effluvium, a stress-related hair loss that can appear a few months after major weight changes. Hair typically grows back once weight stabilizes and nutrition improves. Maintaining adequate protein, iron, zinc, and vitamin D intake may help support hair health.

Without insurance, the medication typically costs about $1,000–$1,200 per month for a 28-day supply in the USA. Coupons, pharmacy discount programs, or savings cards may lower the price slightly, but uninsured patients usually still pay a four-figure monthly cost.

The widely advertised $25 Mounjaro price usually refers to a manufacturer savings card for patients with eligible commercial insurance and a prescription for type 2 diabetes. With qualifying coverage, the savings program may reduce monthly costs to about $25. These offers usually do not apply to Medicare, Medicaid, or uninsured patients.

GLP-1/GIP medication is injected once weekly under the skin. The recommended shot sites are the abdomen, front of the thigh, or upper arm. When injecting in the abdomen, stay at least 2 inches away from the belly button. Rotate injection spots each week to reduce irritation, bruising, or lumps.

Fatigue can occur with dual incretin medication, although digestive side effects such as nausea, diarrhea, and constipation are more common. Tiredness may result from reduced calorie intake, rapid weight loss, dehydration, or dose increases. For many people, fatigue improves after a few weeks once the body adjusts to the medication.

To use a shot pen, check the label and expiration date, clean the jab site with alcohol, and insert the needle at a 90-degree angle under the skin. Press and hold the button until the full dose is delivered. Remove the needle and dispose of it in a sharps container. Always follow the Instructions for Use provided with your pen device.

Yes. Unopened pens should be stored in the refrigerator at 36–46°F (2–8°C). They can be kept at room temperature up to 86°F (30°C) for up to 21 days if needed. Do not freeze the medication, and discard any pen that has been frozen or left out longer than recommended.

Tirzepatide has a half-life of about 5 days, meaning blood levels decrease by half every five days. Most of the drug typically leaves the body about 25–30 days after the last injection.

Constipation is a common side effect of GLP-1/GIP medications. It occurs because the medication slows stomach emptying and gut motility. Drinking more water, increasing fiber intake, and staying physically active may help reduce symptoms.

Both Mounjaro and Zepbound contain tirzepatide, which activates GLP-1 and GIP receptors. The main difference is approval: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. The medications work the same way, but insurance coverage and labeling differ.